MA40030A - Conjugués peptide-médicament - Google Patents

Conjugués peptide-médicament

Info

Publication number
MA40030A
MA40030A MA040030A MA40030A MA40030A MA 40030 A MA40030 A MA 40030A MA 040030 A MA040030 A MA 040030A MA 40030 A MA40030 A MA 40030A MA 40030 A MA40030 A MA 40030A
Authority
MA
Morocco
Prior art keywords
peptide
drug conjugates
linker
self
drug
Prior art date
Application number
MA040030A
Other languages
English (en)
Inventor
Shaosong Chu
Original Assignee
Jiarui Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiarui Biopharmaceuticals Ltd filed Critical Jiarui Biopharmaceuticals Ltd
Publication of MA40030A publication Critical patent/MA40030A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des conjugués peptide-médicament comprenant des lieurs à auto-immolation de carbonate de p-aminobenzylcarbamoyle ou de p-aminobenzolyle. Les conjugués peptide-médicament comprennent une fraction peptidique qui peut être clivée par des protéases cellulaires, liées au lieur à auto-immolation, lequel lieur est lié à une fraction de médicament cytotoxique. Lors du clivage de la fraction peptidique, le lieur s'auto-immole, libérant le médicament cytotoxique sous une forme active. L'invention porte également sur des structures dimères des conjugués peptide-médicament comprenant deux molécules de médicament cytotoxique par conjugué.
MA040030A 2014-06-03 2015-06-01 Conjugués peptide-médicament MA40030A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462007159P 2014-06-03 2014-06-03

Publications (1)

Publication Number Publication Date
MA40030A true MA40030A (fr) 2015-12-10

Family

ID=54700553

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040030A MA40030A (fr) 2014-06-03 2015-06-01 Conjugués peptide-médicament

Country Status (9)

Country Link
US (2) US9579317B2 (fr)
EP (1) EP3152223B1 (fr)
JP (2) JP6539729B2 (fr)
CN (1) CN106456799B (fr)
AU (1) AU2015270924B2 (fr)
CA (1) CA2951049C (fr)
ES (1) ES2857192T3 (fr)
MA (1) MA40030A (fr)
WO (1) WO2015187540A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184540A4 (fr) * 2014-08-22 2018-03-21 Yafei Shanghai Biolog Medicine Science& Technology Corps de couplage à cible micromoléculaire activée de manière spécifique dans un micro-environnement tumoral et son utilisation
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CN107375288B (zh) 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
CA3047491A1 (fr) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Promedicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique
CN108314703B (zh) * 2017-01-17 2022-02-01 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的激酶抑制剂的制备和用途
KR102279429B1 (ko) * 2017-04-21 2021-07-20 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. 멀티 암 표적 항암 콘쥬게이트
CN107670048B (zh) 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
KR20220004618A (ko) * 2019-01-07 2022-01-11 세나 바이오사이언스 아이엔씨. 신규한 펩티드 및 이의 용도
CN114286693A (zh) * 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
US20220313625A1 (en) * 2019-05-24 2022-10-06 The Jikei University Pharmaceutical agent, medicinal solution for cleaning pulmonary alveoli, and nebulizer
EP4237012A1 (fr) * 2020-10-30 2023-09-06 Avacta Life Sciences Limited Conjugués thérapeutiques à demi-vie sérique prolongée activés par fap
WO2022094237A1 (fr) * 2020-10-30 2022-05-05 Avacta Life Sciences Limited Conjugués thérapeutiques à demi-vie sérique étendue activés par enzyme
CN115850288B (zh) * 2022-11-25 2025-03-21 中科帅天医药(深圳)有限公司 一种丝裂霉素c前体药物及其制备方法和应用
WO2024184661A1 (fr) * 2023-03-09 2024-09-12 Bicycletx Limited Synthèse de conjugués de toxine bicycliques, et intermédiaires de ceux-ci
CN117683079B (zh) * 2023-12-12 2025-04-04 九洲药业(杭州)有限公司 一种抗体偶联药物连接子的固相合成方法
WO2025259603A1 (fr) * 2024-06-11 2025-12-18 Crinetics Pharmaceuticals, Inc. Conjugués médicamenteux non peptidiques dirigés contre le récepteur de la somatostatine 2 (sst2r) et leurs utilisations
CN121851112A (zh) * 2026-03-17 2026-04-14 内蒙古大学 环肽毒素类drug-linker及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3803223A (en) * 1970-07-20 1974-04-09 Searle & Co 3-amino-n-substituted succinamic acids and intermediates thereto
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
MXPA02007939A (es) * 2000-02-24 2003-02-10 Genentech Inc Terapia con profarmacos activados por la caspasa.
US8314060B2 (en) 2000-09-05 2012-11-20 Biosight Ltd. Peptide conjugated anti-cancer prodrugs
CA2536357A1 (fr) * 2003-05-29 2004-12-23 The Scripps Research Institute Liberation ciblee sur des cellules exprimant la legumaine
EP1976861A2 (fr) 2005-11-29 2008-10-08 The Scripps Research Institute Inhibition de l'invasion des cellules tumorales, de la metastase et de l'angiogenese
EP2266964B1 (fr) * 2009-06-22 2013-01-09 KTB Tumorforschungsgesellschaft mbH Unités de déclencheur d'acide labile
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2012075472A2 (fr) 2010-12-03 2012-06-07 Regents Of The University Of Colorado, A Body Corporate Entités chimiques et leurs utilisations thérapeutiques

Also Published As

Publication number Publication date
WO2015187540A1 (fr) 2015-12-10
CA2951049A1 (fr) 2015-12-10
CA2951049C (fr) 2023-01-03
JP2019189623A (ja) 2019-10-31
JP2017521486A (ja) 2017-08-03
US20170232023A1 (en) 2017-08-17
ES2857192T3 (es) 2021-09-28
AU2015270924A1 (en) 2016-12-15
CN106456799A (zh) 2017-02-22
EP3152223A1 (fr) 2017-04-12
EP3152223B1 (fr) 2020-11-25
US20150343083A1 (en) 2015-12-03
CN106456799B (zh) 2020-05-22
EP3152223A4 (fr) 2017-12-20
US9579317B2 (en) 2017-02-28
JP6539729B2 (ja) 2019-07-03
AU2015270924B2 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
CY1123675T1 (el) Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου
ZA201903667B (en) Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
MX2021008334A (es) Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco.
PH12016501995A1 (en) Tubulysin derivatives
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CL2016001514A1 (es) Conjugado de anticuerpo-farmaco que posee un resto quimico no peptidico, que puede ser escindido por la catepsina b; uso para la fabricacion de un medicamento util y conjugacion farmaceutica.
PH12016500246A1 (en) 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
NZ754810A (en) Pyrrolobenzodiazepine-antibody conjugates
WO2014062697A3 (fr) Conjugués d'administration de médicament contenant des acides aminés artificiels et procédés d'utilisation
MX2021004884A (es) Conjugado anticuerpo anti-factor de crecimiento epidermico humano 3 (anti-her3-farmaco).
MX2018010247A (es) Nuevos conjugados de amanitina.
HK1222122A1 (zh) 选择性药物递送组合物及使用方法
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
NZ703581A (en) Anti-cd70 antibody drug conjugates
PH12015501422B1 (en) Hydrophilic self-immolative linkers and conjugates thereof
NZ710729A (en) Amatoxin derivatives
IN2015DN02577A (fr)
MX2016007578A (es) Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MY169147A (en) Drug-protein conjugates
MX344009B (es) Conjugados de amatoxinas con enlaces mejorados.
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
CL2013003393A1 (es) Inmunoconjugados (conjugados anticuerpo-fármaco) que en su estructura contienen un agente de unión al surco menor del adn (compuesto derivado de cbi), un grupo fosfato como grupo profármaco (protector) y un conector peptídico, útiles para el tratamiento de cáncer.